Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia

Cancer
Deborah A ThomasHagop Kantarjian

Abstract

Adult Burkitt-type lymphoma (BL) and acute lymphoblastic leukemia (B-ALL) are rare entities composing 1% to 5% of non-Hodgkin lymphomas NHL) or ALL. Prognosis of BL and B-ALL has been poor with conventional NHL or ALL regimens, but has improved with dose-intensive regimens. To evaluate the addition of rituximab, a CD20 monoclonal antibody, to intensive chemotherapy in adults with BL or B-ALL, 31 patients with newly diagnosed BL or B-ALL received the hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) regimen with rituximab. Their median age was 46 years; 29% were 60 years or older. Rituximab 375 mg/m(2) was given on Days 1 and 11 of hyper-CVAD courses and on Days 1 and 8 of methotrexate and cytarabine courses. Complete remission (complete response [CR]) was achieved in 24 of 28 (86%) evaluable patients; 3 had a partial response, and 1 had resistant disease. There were no induction deaths. The 3-year overall survival (OS), event-free survival, and disease-free survival rates were 89%, 80%, and 88%, respectively. Nine elderly patients achieved CR with all of them in continuous CR (except 1 death in CR from infection), with a 3-year OS rate of 89%. Multivariate analysis of current and hist...Continue Reading

Associated Clinical Trials

References

Jun 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H M KantarjianB Barlogie
Feb 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A ReiterH Riehm
Sep 30, 1993·The New England Journal of Medicine·UNKNOWN International Non-Hodgkin's Lymphoma Prognostic Factors Project
Apr 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P BowmanS Murphy
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Nov 24, 1999·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D A ThomasH Kantarjian
Nov 9, 2000·Leukemia·A StamatoullasH Tilly
Feb 24, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseR I Fisher
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J C ByrdI W Flinn
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·S M O'BrienM J Keating
Jan 25, 2002·The New England Journal of Medicine·Bertrand CoiffierChristian Gisselbrecht
Aug 16, 2002·Annals of Oncology : Official Journal of the European Society for Medical Oncology·G M MeadUNKNOWN UKLG LY06 collaborators
Apr 17, 2004·British Journal of Haematology·Maaike J de VriesChristian M Zwaan
Jul 22, 2004·Blood·Kristie A BlumJohn C Byrd
Mar 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael J KeatingHagop Kantarjian

❮ Previous
Next ❯

Citations

Dec 4, 2008·Annals of Hematology·Yok-Lam KwongJoyce C W Chan
May 3, 2013·Annals of Hematology·Igor AurerJosip Joachim Grah
Jun 21, 2002·Current Treatment Options in Oncology·Andrew M Evens, Leo I Gordon
Dec 1, 2006·Current Hematologic Malignancy Reports·Ian T Magrath
Jul 1, 2007·Current Hematologic Malignancy Reports·Farhad RavandiHagop Kantarjian
Jul 1, 2008·Current Hematologic Malignancy Reports·Daniel J DeAngelo, Richard M Stone
Jul 1, 2008·Current Hematologic Malignancy Reports·Thomas G Gross, Amanda M Termuhlen
Apr 29, 2010·Current Hematologic Malignancy Reports·Alan S Wayne
Aug 4, 2010·Current Hematologic Malignancy Reports·Margaret T Kasner
Dec 31, 2010·Current Hematologic Malignancy Reports·Deborah A ThomasHagop Kantarjian
Mar 30, 2013·Current Hematologic Malignancy Reports·Naval Daver, Susan O'Brien
Nov 10, 2007·Current Oncology Reports·Thomas G Gross, Amanda M Termuhlen
Oct 23, 2008·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Andrés J Muñoz MartínPilar García Alfonso
Aug 4, 2012·Bone Marrow Transplantation·S O AhmedM Aljurf
Feb 3, 2007·Nature Reviews. Drug Discovery·Ching-Hon Pui, Sima Jeha
May 29, 2007·Oncogene·B Coiffier
Nov 15, 2013·The New England Journal of Medicine·Jeffrey A BarnesAliyah R Sohani
Feb 23, 2008·AIDS Patient Care and STDs·Victoria S BlinderJohn P Leonard
Feb 23, 2011·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J A BarnesJ S Abramson
Mar 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·T WästerlidM Jerkeman
Oct 23, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·A M EvensL I Gordon
Sep 29, 2011·Current Opinion in Oncology·Koen van Besien
May 31, 2007·Current Opinion in Hematology·Jason T Yustein, Chi V Dang
Jun 10, 2008·Current Opinion in Hematology·Sarah Larson, Wendy Stock
Jan 17, 2008·Current Opinion in Pediatrics·Dina Attias, Sheila Weitzman
Feb 22, 2013·Journal of Pediatric Hematology/oncology·Paola ZangariStefania Bernardi
Jun 3, 2009·Clinical Nuclear Medicine·Wanzhen ZengRaghuveer Halkar
Oct 19, 2010·Journal of Oncology·Jason M God, Azizul Haque
Dec 24, 2010·Cancer Research·Mark P ChaoRavindra Majeti
Dec 17, 2008·Hematology·Archibald S Perkins, Jonathan W Friedberg

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.